Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02116660
LAAM-HAART PET Imaging
- Conditions
- Interventions
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT01935830
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 499
- Registration Number
- NCT01910402
- Locations
- 🇬🇧
GSK Investigational Site, Tooting, London, United Kingdom
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01907724
The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 40
- Registration Number
- NCT01896622
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01825980
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
- Conditions
- Interventions
- First Posted Date
- 2013-03-21
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1443
- Registration Number
- NCT01815736
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Southwest Infectious Disease Clinical Research, Inc., Dallas, Texas, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01813552
A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 8
- Registration Number
- NCT01810887
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 107
- Registration Number
- NCT01803074
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.